The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules

The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules

The Food and Drug Administration approved 59 new drugs (42 New Chemical Entities and 17 Biologics) during 2018. This number breaks the previous record of 53 approved by the same organization in 1996. The 17 new biologics approved in 2018 also represent an important milestone for this kind of drug an...

Full description

Bibliographic Details
Main Authors: Beatriz G. de la Torre, Fernando Albericio
Format: Article
Language:English
Published: MDPI AG 2019-02-01
Series:Molecules
Subjects:
antibodies
API
biologics
chemical entities
drug discovery
fluorine based drugs
natural products
oligonucleotides
peptide
TIDES
small molecules
Online Access:https://www.mdpi.com/1420-3049/24/4/809
Description
Summary:The Food and Drug Administration approved 59 new drugs (42 New Chemical Entities and 17 Biologics) during 2018. This number breaks the previous record of 53 approved by the same organization in 1996. The 17 new biologics approved in 2018 also represent an important milestone for this kind of drug and they clearly exceed the 12 approved in 2015 and 2017. Herein, the 59 new drugs of the class of 2018 are analyzed from a strictly chemical perspective. The classification has been carried out on the basis of the chemical structure and includes the following: Biologics (antibodies and enzymes); TIDES (peptides and oligonucleotides) and natural products; drug combinations; and small molecules.
ISSN:1420-3049

Similar Items